Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
  • LinkedIn
  • Instagram
Research ArticlePractice

Type 2 diabetes and ASA

G. Michael Allan, Noah Ivers and James McCormack
Canadian Family Physician July 2010; 56 (7) 664;
G. Michael Allan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Noah Ivers
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James McCormack
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Clinical question

Should acetylsalicylic acid (ASA) be recommended for all patients who have type 2 diabetes but no history of cardiovascular disease (CVD)?

Evidence

Two recent randomized controlled trials of ASA in type 2 diabetics addressed this question.

  • The JPAD (Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes) study1 examined 2539 patients with type 2 diabetes taking low-dose ASA (81 to 100 mg) or nothing for a median of 4.4 years.

    • -CVD events were not significantly different:

      • —5.4% for those taking ASA versus 6.7% for those not taking ASA (P = .16).

    • -Bleeding events (hemorrhagic stroke and severe gastrointestinal bleeding) were not significantly different.

    • -In patients older than 65 years (prespecified subgroup), ASA reduced CVD events:

      • —6.3% for those taking ASA versus 9.2% for those not taking ASA (P = .047; number needed to treat = 35).

  • The POPADAD (Prevention of Progression of Arterial Disease and Diabetes) study2 followed 1276 patients with type 2 diabetes (with asymptomatic peripheral artery disease) taking low-dose ASA (100 mg) or placebo for a median of 6.7 years.

    • -CVD events were not significantly different:

      • —18.2% for those taking ASA versus 18.3% for those taking placebo (P = .86).

    • -Gastrointestinal bleeding events were not significantly different (P = .69).

Context

These findings are supported by the PPP (Primary Prevention Project) study of higher-risk patients without history of CVD.3

  • In those with diabetes (1031 patients), ASA did not result in a statistically significant difference in CVD events.

  • Those without diabetes (3753 patients) who had 1 or more risk factors for CVD had a statistically significant benefit with ASA (P = .03).

A recent meta-analysis combined JPAD1 and POPADAD2 with subgroups of patients with diabetes extracted from other studies and also found no overall advantage for ASA in primary prevention for those with type 2 diabetes.4

Canadian Diabetes Association guidelines5 correctly suggest that ASA is not necessary in all patients with diabetes but that it could be considered in “high-risk” groups.

  • Their definition of high-risk includes men 45 years or older, women 50 years or older, patients with microvascular or macrovascular disease, those with family history of CVD, those who have had diabetes for more than 15 years, or those with an extreme level of a single risk factor (eg, low-density lipoprotein > 5.0 mmol/L).

  • However, this high-risk group includes patients who did not benefit from ASA in the latest studies.1–3

High-quality evidence has not clearly identified which “high-risk” patients with diabetes will benefit from ASA (except perhaps those aged 65 or older).

Bottom line

According to current evidence, ASA should not be universally recommended for patients with type 2 diabetes who have no history of CVD.

Implementation

Prescribe ASA to patients with diabetes judiciously and alter flow sheets, checklists, or current standards of care accordingly. In 1 study,1 the patients with diabetes who benefited from ASA had a mean 10-year CVD risk of more than 20%. You can estimate risk periodically by linking to online6 calculators (or adding paper-based7 calculators) in patients’ charts. Patients’ estimated CVD risk can inform discussion regarding starting (or stopping) low-dose ASA.

Notes

Tools for Practice articles in Canadian Family Physician are adapted from articles published twice monthly on the Alberta College of Family Physicians (ACFP) website, summarizing medical evidence with a focus on topical issues and practice-modifying information. The ACFP summaries and the series in Canadian Family Physician are coordinated by Dr G. Michael Allan, and the summaries are co-authored by at least 1 practising family physician. Feedback is welcome and can be sent to toolsforpractice{at}cfpc.ca. Archived articles are available on the ACFP website: www.acfp.ca.

Footnotes

  • The opinions expressed in this Tools for Practice article are those of the authors and do not necessarily mirror the perspective and policy of the Alberta College of Family Physicians.

  • Copyright© the College of Family Physicians of Canada

References

  1. ↵
    1. Ogawa H,
    2. Nakayama M,
    3. Morimoto T,
    4. Uemura S,
    5. Kanauchi M,
    6. Doi N,
    7. et al
    . Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300(18):2134-41. Erratum in: JAMA 2009;301(18):1882.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Belch J,
    2. MacCuish A,
    3. Campbell I,
    4. Cobbe S,
    5. Taylor R,
    6. Prescott R,
    7. et al
    . The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a1840. DOI: 10.1136/bmj.a1840.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Sacco M,
    2. Pellegrini F,
    3. Roncaglioni MC,
    4. Avanzini F,
    5. Tognoni G,
    6. Nicolucci A
    . Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003;26(12):3264-72.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. De Berardis G,
    2. Sacco M,
    3. Strippoli GF,
    4. Pellegrini F,
    5. Graziano G,
    6. Tognoni G,
    7. et al
    . Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009;339:b4531. DOI: 10.1136/bmj.b4531.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Fitchett D,
    2. Kraw M
    . Vascular protection in people with diabetes. Can J Diabetes 2008;32(Suppl 1):S102-6.
    OpenUrl
  6. ↵
    1. Payne R
    . University of Edinburgh Cardiovascular Risk Calculator [online tool]. Edinburgh, UK: University of Edinburgh; 2010. Available from: http://cvrisk.mvm.ed.ac.uk/calculator/calc.asp. Accessed 2010 May 19.
  7. ↵
    1. National Prescribing Service
    . New Zealand Cardiovascular Risk Calculator [printable tool]. Surry Hills, NSW: National Prescribing Service; 2004. Available from: www.qml.com.au/Files/CardioRiskCalc.pdf. Accessed 2010 May 19.
PreviousNext
Back to top

In this issue

Canadian Family Physician: 56 (7)
Canadian Family Physician
Vol. 56, Issue 7
1 Jul 2010
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Type 2 diabetes and ASA
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Type 2 diabetes and ASA
G. Michael Allan, Noah Ivers, James McCormack
Canadian Family Physician Jul 2010, 56 (7) 664;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Type 2 diabetes and ASA
G. Michael Allan, Noah Ivers, James McCormack
Canadian Family Physician Jul 2010, 56 (7) 664;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Clinical question
    • Evidence
    • Context
    • Bottom line
    • Implementation
    • Notes
    • Footnotes
    • References
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Practice

  • Effectiveness of dermoscopy in skin cancer diagnosis
  • Spontaneous pneumothorax in children
  • Is 45 the new 50 in colorectal cancer screening?
Show more Practice

Tools for Practice

  • Testosterone supplementation for men
  • Time to challenge penicillin allergy labels
  • Antibiotics for acute diverticulitis
Show more Tools for Practice

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • LinkedIn
  • Instagram
  • RSS Feeds

Copyright © 2025 by The College of Family Physicians of Canada

Powered by HighWire